Quick Takeaways
- Novo Holdings A/S filed SCHEDULE 13D/A for Edgewise Therapeutics, Inc. Common Stock, par value $0.0001 per share (EWTX).
- Disclosed ownership: 4.9%.
- Date of event: 23 Apr 2026.
Novo Holdings A/S - 23 Apr 2026 SCHEDULE 13D/A Report for Edgewise Therapeutics, Inc. Common Stock, par value $0.0001 per share (EWTX)
- Filing Manager
- Novo Holdings A/S
- Reporting Manager
- Novo Holdings A/S
- Symbol
- EWTX
- Shares outstanding
- 109,183,673 shares
- Disclosed Ownership
- 5,350,000 shares
- Ownership
- 4.9%
- Form type
- SCHEDULE 13D/A
- Filing time
- 27 Apr 2026, 16:49:16 UTC
- Date of event
- 23 Apr 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Novo Holdings A/S disclosed 4.9% ownership in Edgewise Therapeutics, Inc. Common Stock, par value $0.0001 per share (EWTX) on 23 Apr 2026."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 27 Apr 2026, 16:49.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Novo Holdings A/S | 4.9% | 5,350,000 | 5,350,000 | 0 | /s/ Barbara Fiorini | By Barbara Fiorini, General Counsel, Finance & Operations | 0001388325 |